

<b>Reference:</b>	FOI.18038.25
<b>Subject:</b>	Asthma medications
<b>Date of Request:</b>	8 August 2025

**Requested:**

1. How many patients have been treated (for any condition) in the last 4 months with:
  - Benralizumab
  - Dupilumab
  - Omalizumab
  - Reslizumab
  - Mepolizumab
  - Tezepelumab
  
2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:
  - Age 6-11
  - Age 12-17
  - Age 18 and above
  
3. How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with:
  - Dupilumab
  - Omalizumab
  
4. How many patients have been diagnosed with BOTH chronic sinusitis (ICD-10 code J32) AND nasal polyps (ICD-10 code J33) in the past year? Of these patients, how many have been treated in the last 4 months with:
  - Benralizumab
  - Dupilumab
  - Omalizumab
  - Reslizumab
  - Mepolizumab
  - Tezepelumab

**Response:**

1. Hywel Dda University Health Board (UHB) provides within the table below, the number of patients treated with the listed medications, for any condition, during the period 1 April to 31 July 2025.

Medication	Number
Benralizumab	99
Dupilumab	131
Omalizumab	21
Reslizumab	0

Mepolizumab	30
Tezepeluma	110

2. The UHB provides within the table below, the number of patients that received the medications detailed in question 1, by the requested age ranges, during the period 1 April to 31 July 2025.

Age range	Number
6 to 17	8
12-17	11
18 and over	370

3. The UHB provides within the table below, the number of respiratory patients that have been treated with the medications listed, during the period 1 April to 31 July 2025.

Medication	Number
Dupilumab	12
Omalizumab	0

4. The UHB confirms that nine (9) patients have been diagnosed with both chronic sinusitis and nasal polyps, as recorded on the UHB's Welsh Patient Administration System (WPAS). None of these patients received the medications listed during the period 1 April to 31 July 2025.